The same trend, although not significant, was found when PBMC from three CLL patients (Fig. 7) with 80% or more CD19+ CD5+ ROR1+ cells were used as target cells (Fig. 9B). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.